Ki67 assessment, digital image analysis, and PAM50/Prosigna subtype divergence in early ER-positive breast cancer
Federica Zito Marino, Martina Amato, Giuseppe D’abbronzo, Alessandra Biasi et autres
0 citationsJournal of Translational Medicine
Grazia Arpino
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
362Publications signalées
10515Citations signalées
2Affiliations récentes
Institutions déclarées
Domaines associés
Advanced Breast Cancer TherapiesBreast Cancer Treatment StudiesHER2/EGFR in Cancer ResearchCancer Treatment and PharmacologyCancer Cells and Metastasis
Publications récentes
Tumor-Infiltrating Lymphocytes as a Predictor of Adjuvant Avelumab Efficacy in Patients with High-risk Triple-Negative Breast Cancer
Maria Vittoria Dieci, Elisa Gasparini, Lorenzo Nicolè, Peter Schmid et autres
0 citationsClinical Cancer Research
Real-world evidence of sacituzumab govitecan in metastatic triple-negative breast cancer: an updated multicenter analysis
Roberta Caputo, Giuseppe Buono, C. Martinelli, A. Botticelli et autres
0 citationsESMO Open
Efficacy and safety of first-line systemic therapies for patients with metastatic triple negative breast cancer ineligible for anti-PD-(L)1 inhibitors in clinical practice: a systematic review and network meta-analysis
Aldo Caltavituro, G Grazia, Anna Aguilera, Roberto Buonaiuto et autres
0 citationsResearch Square
Supplementary Methods S1 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
Giampaolo Bianchini, Luca Malorni, Roberta Caputo, Alberto Zambelli et autres
0 citations
Supplementary Figure S1 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
Giampaolo Bianchini, Luca Malorni, Roberta Caputo, Alberto Zambelli et autres
0 citations
Supplementary Figure S3 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
Giampaolo Bianchini, Luca Malorni, Roberta Caputo, Alberto Zambelli et autres
0 citations
Supplementary Figure S2 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
Giampaolo Bianchini, Luca Malorni, Roberta Caputo, Alberto Zambelli et autres
0 citations
Supplementary Data S1 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
Giampaolo Bianchini, Luca Malorni, Roberta Caputo, Alberto Zambelli et autres
0 citations
Supplementary Table S3 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
Giampaolo Bianchini, Luca Malorni, Roberta Caputo, Alberto Zambelli et autres
0 citations
Supplementary Table S2 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
Giampaolo Bianchini, Luca Malorni, Roberta Caputo, Alberto Zambelli et autres
0 citations
Supplementary Table S4 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
Giampaolo Bianchini, Luca Malorni, Roberta Caputo, Alberto Zambelli et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.